NuCana (NCNA)
NasdaqCM: NCNA
· Real-Time Price · USD
1.52
-0.01 (-0.65%)
At close: Aug 21, 2026, 3:58 PM
1.50
-1.32%
After-hours: 7:30 PM
The price, the headline numbers and the latest news, in one place.
NuCana (NCNA) Stock Price, Analysis & Data
-0.65% (1D)
| Bid | 1.08 |
| Market Cap | 6.33M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -9.71M |
| 2.22 | |
| 67.99 | |
| 0.02 | |
| -0.16 | |
| P/B (ttm) | 0.21 |
| P/S (ttm) | n/a |
| Earnings Date | n/a |
| Ask | 2 |
| Volume | 18,250 |
| Avg. Volume (20D) | 49,254 |
| Open | 1.50 |
| Previous Close | 1.53 |
| Day's Range | 1.50 - 1.55 |
| 52-Week Range | 1.21 - 7.22 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About NCNA
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer in the United States. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company is developing medicines to overcome the limitations of nucleoside analogs and generate concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3...
Industry Biotechnology
Sector Healthcare
IPO Date Sep 28, 2017
Employees 10
Stock Exchange NasdaqCM
Ticker Symbol NCNA
Website https://www.nucana.com
Financial Performance
In 2025, NuCana's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -29.35M, an increase of 54.51%.
Financial StatementsEarnings Surprise
NuCana has released their quarterly earnings on Mar 20, 2025:
- Revenue of $0 misses estimates by $0, with NaN% YoY growth.
- EPS of -64.85 exceeds estimates by 375.15, with 92.71% YoY growth.
Page 1 of 2